Citations

Mayo Clinic

Clear

627 citation(s) found for "Qu, Shen".

Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study
Weiner, Julia, Smith, Tristin , Hoy, Claire K., Sarosh, Cyrus , Madison, Jacqueline A. , Ambati, Amala, Tambralli, Ajay , Peters, Noah F., Packel, Corinne, Gockman, Kelsey, Zuo, Yu , Briceño, Emily M. , Knight, Jason S , Zuo, Yu , Sarosh, Cyrus , Madison, Jacqueline A , Ambati, Amala, Nagaraja, Vivek

ACR Open Rheumatology | December 3, 2022 | Volume: 5 | Issue: 1 | Pages: 28-37

10.1002/acr2.11512 | PMID 36461647 Get It

ObjectiveThis study assessed patient‐reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life.MethodsPatients completed Patient‐Reported Outcomes Measurement Information System Physical Function (PF) and Cognitive Function (CF) Short Forms as well as the pain intensity (PI) rating (scale of 1‐10). Patients were characterized for demographics, clinical manifestations of antiphospholipid syndrome (APS), cardiovascular risk factors, laboratory test results, and medication usage. Multivariate modeling was done via linear regression.ResultsOf 139 patients, 89 had primary APS, 21 had secondary APS, and 29 had persistent aPL without meeting clinical criteria for APS. The average T scores (±SD) for PF and CF were 45.4 ± 9.2 and 48.6 ± 11.6, respectively; the average for PI was 3.0 ± 2.6. Approximately half of the patients (47%) endorsed at least mild impairment in PF (T score < 45). Mean PF, CF, and PI did not differ between diagnostic groups. Individuals who endorsed more impairment on one measure also tended to endorse more impairment on another (Pearson r = 0.43‐0.59). In the multivariate models, age, smoking, pain medications, and serotonergic medications were associated with impairment in at least one PRO domain. The Damage Index for APS was significantly correlated with both PF and CF.ConclusionIndividuals living with APS endorsed more impairment in PF (and potentially CF) than expected for the general population. The relationship between certain medications and PROs warrants further study, as does the longitudinal trajectory of these and other PROs.
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Sharplin, Kirsty, Chhetri, Rakchha , Ladon, Dariusz, Al‐Kali, Aref , Litzow, Mark R. , Mangaonkar, Abhishek A. , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede, Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Kutyna, Monika , Wang, Paul Po-Shen , Alkhateeb, Hassan B. , Ross, David M , Yeung, David , Shanmuganathan, Naranie , Hogan, William J. , Kumar, Sharad , Singhal, Deepak , Brown, Anna , Scott, Hamish S. , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859 Get It

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
Zhu, Yuan Xiao , Chesi, Marta, Chen, Yi , Tan, Felai, Anthony, Stephen P. , Chen, Yu , Fonseca, Rodrigo , Bergsagel, P. Leif , Chesi, Marta , Pandey, Akhilesh , Mangalaparthi, Kiran K. , Shen, Yue Guo , Dai, Bing, Braggio, Esteban , Fonseca, Rafaël

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7129-7130

10.1182/blood-2022-167372 Get It

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O. , Forcade, Édouard , Muñoz, Javier, Guibert, Sophie de , Lin, Yi , Deol, Abhinav , McSweeney, Peter A., Kersten, Marie José , Jacobson, Caron A. , Thiéblemont, Catherine , Timmerman, John M. , Stiff, Patrick J. , Tzachanis, Dimitrios , Zheng, Yan , Vardhanabhuti, Saran , Shen, Rhine R. , Miao, Harry , Kim, Jenny , Oluwole, Olalekan O , Vose, Julie M. , Bartlett, Nancy L. , Goy, Andre Henri , Farooq, Umar , Minnema, Monique C , Avivi, Irit , Nater, Jenny , Meerten, Tom van

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10399-10401

10.1182/blood-2022-156117 Get It

CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
Krysiak, Kilannin , Danos, Arpad , McMichael, Joshua F. , Coffman, Adam , Kiwala, Susanna , Sheta, Lana , Kujan, Lynzey , Pema, Shahil , Ridd, Sarah , Spies, Nicholas C. , Andric, Veronica , Chiorean, Andreea , Rieke, Damian , Clark, Kaitlin A., Reisle, Caralyn , Venigalla, Ajay C, Jani, Payal , Takahashi, Hideaki , Suda, Avila, Horak, Peter , Ritter, Deborah , DeLong, Sean , Lamping, Mario , Shen, Haolin , Marr, Alexander , Hoang, My , Singhal, Kartik , Khanfar, Mariam , Li, Brian V , Lin, Wan‐Hsin , Terraf, Panieh, Corson, Laura , Salama, Yasser, Farncombe, Kirsten M. , Ji, Jianling , Zhao, Xiaonan, Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Walker, Jason , Zhang, Jinghui , Patel, Ronak Y. , Kim, Raymond H. , Jones, Steven J.M. , Raca, Gordana , Madhavan, Subha , Griffith, Malachi , Griffith, Obi L. , Coffman, Adam C , Kiwala, Susanna , Zhou, Xin , Campbell, Katie M , Ji, Jianling , Cotto, Kelsy C , Schriml, Lynn M , Wagner, Alex H , Griffith, Malachi , Griffith, Obi L , Krysiak, Kilannin , Kanagal-Shamanna, Rashmi , Kim, Raymond H , Saliba, Jason , Barnell, Erica K. , Grisdale, Cameron J. , Lever, Jake , Venigalla, Ajay , Evans, Mark G. , Ainscough, Benjamin J. , Kesserwan, Chimene A. , Zhao, Xiaonan, King, Ian F. G. , Skidmore, Zachary L. , Milosavljevic, Aleksandar , Giles, Rachel H. , Mardis, Elaine R. , Rao, Shruti , Wagner, Alex H. , Khanfar, Mariam

Nucleic Acids Research | October 15, 2022 | Volume: 51 | Issue: D1 | Pages: D1230-D1241

10.1093/nar/gkac979 | PMID 36373660 Get It

Abstract CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence Items) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new Evidence Types (Predisposing, Oncogenic and Functional). The growing CIViC knowledgebase has over 300 contributors and distributes clinically-relevant cancer variant data currently representing &gt;3200 variants in &gt;470 genes from &gt;3100 publications.
Technical note: Investigation of dose and LETd effect to rectum and bladder by using non‐straight laterals in prostate cancer receiving proton therapy
Yang, Yunze, Rwigema, Jean‐Claude M. , Vargas, Carlos , Yu, Nathan Y. , Keole, Sameer R., Wong, William W. , Shen, Jiajian , Schild, Steven E. , Shen, Jiajian , Bues, Martin , Liu, Wei

Medical Physics | October 8, 2022 | Volume: 49 | Issue: 12 | Pages: 7428-7437

10.1002/mp.16008 | PMID 36208196 Get It

AbstractBackgroundParallel‐opposed lateral beams are the conventional beam arrangements in proton therapy for prostate cancer. However, when considering linear energy transfer (LET) and RBE effects, alternative beam arrangements should be investigated.PurposeTo investigate the dose and dose averaged LET (LETd) impact of using new beam arrangements rotating beams 5°–15° posteriorly to the laterals in prostate cancer treated with pencil‐beam‐scanning (PBS) proton therapy.MethodsTwenty patients with localized prostate cancer were included in this study. Four proton treatment plans for each patient were generated utilizing 0°, 5°, 10°, and 15° posterior oblique beam pairs relative to parallel‐opposed lateral beams. Dose‐volume histograms (DVHs) from posterior oblique beams were analyzed. Dose‐LETd‐volume histogram (DLVH) was employed to study the difference in dose and LETd with each beam arrangement. DLVH indices, , defined as the cumulative absolute volume that has a dose of at least d (Gy[RBE]) and a LETd of at least l (keV/µm), were calculated for both the rectum and bladder to the whole group of patients and two‐sub groups with and without hydrogel spacer. These metrics were tested using Wilcoxon signed‐rank test.ResultsRotating beam angles from laterals to slightly posterior by 5°–15° reduced high LETd volumes while it increased the dose volume in the rectum and increased LETd in bladders. Beam angles rotated five degrees posteriorly from laterals (i.e., gantry in 95° and 265°) are proposed since they achieved the optimal balance of better LETd sparing and minimal dose increase in the rectum. A reduction of V(50 Gy[RBE], 2.6 keV/µm) from 7.41 to 3.96 cc (p < 0.01), and a slight increase of V(50 Gy[RBE], 0 keV/µm) from 20.1 to 21.6 cc (p < 0.01) were observed for the group without hydrogel spacer. The LETd sparing was less effective for the group with hydrogel spacer, which achieved the reduction of V(50 Gy[RBE], 2.6 keV/µm) from 4.28 to 2.10 cc (p < 0.01).ConclusionsPosterior oblique angle plans improved LETd sparing of the rectum while sacrificing LETd sparing in the bladder in the treatment of prostate cancer with PBS. Beam angle modification from laterals to slightly posterior may be a strategy to redistribute LETd and perhaps reduce rectal toxicity risks in prostate cancer patients treated with PBS. However, the effect is reduced for patients with hydrogel spacer.
In vitroassessment of chemokine receptor-ligand interactions mediating mouse eosinophil migration
Borchers, Michael T. , Ansay, Tracy, DeSalle, Rob , Daugherty, Bruce L. , Shen, Huahao , Lee, Nancy A., Lee, James J. , Metzger, Michael J.

Journal of Leukocyte Biology | September 28, 2022 | Volume: 71 | Issue: 6 | Pages: 1033-1041

10.1189/jlb.71.6.1033 Get It

AbstractEosinophil migration from circulation is controlled, in part, by chemokines through a family of G-protein-coupled chemokine receptors (CCR). Studies of human eosinophils have demonstrated that signaling through CCR3 receptors is a prominent pathway leading to chemotaxis, although several other receptor-ligand interactions also appear to mediate eosinophil recruitment. The availability of genetically unique strains of mice permits a reductionist approach to assess the signaling pathways in experimental models of human disease. However, despite similarities in these pathways between mice and humans, significant species differences exist, complicating the translation of results from animal models to humans. Purified mouse eosinophils were used in this study to investigate the chemokine receptor expression and the activities of 18 chemokines. Mouse eosinophils isolated from IL-5 transgenic mice expressed transcripts encoding the chemokine receptors CCR1, CCR2, CCR3, CCR5, CCR8, CXCR2, and CXCR4, but not CCR4. Mouse eosinophils also migrated in response to human and mouse eotaxin-1 and -2, but not human eotaxin-3. In addition, the induced migration of mouse eosinophils by TARC, MIP-1β, and KC suggests that unidentified receptor-ligand interactions contribute to eosinophil recruitment. It is interesting that the potent chemoattractant of human eosinophils, RANTES, was unable to mediate mouse eosinophil migration. Furthermore, despite the ability of MIP-1α to bind receptors on purified mouse eosinophils, it was only able to induce significant eosinophil migration in a mixed splenocyte population and was unable to induce migration of highly purified eosinophils. Collectively, these observations reveal physiologically relevant distinctions in mechanisms mediating human and mouse eosinophil migration that potentially reflect evolutionary disparities between these species.
Evaluation of Treatment Effect in Underrepresented Population in Cancer Trials: Discussion with International Regulators
Sridhara, Rajeshwari , Marchenko, Olga , Barksdale, Elizabeth , Gwise, Thomas, Hess, Lorenzo , Mandrekar, Sumithra J. , Rantell, Khadija , Raven, Andrew, Shen, Yuan-Li, Tendler, Craig , Theoret, Marc R. , Jiang, Qi , Chen, Jie , Dreyer, Nancy A , Fashoyin-Aje, Lola , Garrett‐Mayer, Elizabeth , Gormley, Nicole , Pignatti, Francesco , Raven, Andrew, Singh, Harpreet, Pazdur, Richard M.

Statistics in Biopharmaceutical Research | September 23, 2022 | Volume: 15 | Issue: 2 | Pages: 450-456

10.1080/19466315.2022.2128404 Get It

A novel method for handling Missing Not at Random Data in the electronic health records
Shen, Xinpeng , Ma, Sisi , Vemuri, Prashanthi , Simon, György , Vemuri, Prashanthi , Caraballo, Pedro J.

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 21-26

10.1109/ichi54592.2022.00015 Get It

Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Banerjee, Imon , Jeong, Jiwoong , R, Amith Seri, Barry, Timothy , Neuman, Hana, Campany, Megan , Abdou, Merna , O'Shea, Michael P., Smith, Sean B. , Abraham, Bishoy , Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher, Shen, Win‐Kuang , Grogan, Martha , Kane, G C, Oh, Jae K. , Patel, Bhavik N. , Banerjee, Imon , Li, James , Chao, Chieh‐Ju , O’Shea, Michael, Alsidawi, Said , Oh, Jae K. , Arsanjani, Reza

No container title available | September 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166257188.84471102/v1 Get It

Aims Increased LV wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 to 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4 chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: CA: 0.90, HCM: 0.93, and HTN/other: 0.92). Conclusion The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.